Fundamental differences during Gram-positive versus Gram-negative sepsis become apparent during bacterial challenge of D-galactosamine-treated mice

Innate Immunity

Volumn 4, Issue 3, 1997, Pages 173-181

  Silverstein, R ^a   Norimatsu, M ^a   Morrison, D C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958228217     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/096805199700400302     Document Type: Article

References (45)

1. Bone R.C., Fisher C.J., Clemmer T.P.et al.Sepsis syndrome: valid clinical entity. Crit Care Med 1989; 17: 389-393.
2. Barriere S.L., Lowry S.F. An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23: 376-393.
3. Bone R.C. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457-469.
4. Bone R.C., Fisher Jr C.J., Clemmer T.P.et al.A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
5. Slotman G.J., Fisher Jr C.J., Bone R.C., Clemmer T.P., Metz C.A. and The Methylprednisolone Severe Sepsis Study Group. Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. Crit Care Med 1993; 21: 191-195.
6. Wortel C.H., von der Mm̈hlen M.A.M., van Deventer S.J.H.et al.Effectiveness of a human monoclonal anti-endotoxin (HA-1A) in Gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 1992; 166: 1367-1374.
7. Greenman R.L., Schein R.M.H., Martin M.A.et al.A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266: 1097-1102.
8. Greisman S.E., Johnston C.A. Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negative bacterial sepsis. J Endotoxin Res 1997; 4: 123-154.
9. McCabe W.R. Correspondence re: Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negative bacterial sepsis. J Endotoxin Res 1997; 4: 155-160.
10. Cross A.S., Opal S. Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? J Endotoxin Res 1994; 1:57-69.
11. Mornson D.C., Danner R., Dinarello C.A.et al.Bacterial endotoxins and pathogenesis of Gram-negative infections: current status and future directions. J Endotoxin Res 1994; 1: 71-83.
12. Carswell E.A., Old L.J., Kassel S., Green N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-3670.
13. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-871.
14. Tracey K.J., Fong Y., Hesse D.G.et al.Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664.
15. Ashkenazi A., Marsters S.A., Capon D.J.et al.Protection against endotoxin shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991; 88: 10535-10539.
16. Freudenberg M.A., Galanos C. Tumor necrosis factor alpha mediates lethal activity of killed Gram-negative and Gram-positive bacteria in D-galactosamine-treated mice. Infect Immun 1991; 59: 210-215.
17. Garcia I., Miyazaki Y., Araki K.et al.Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol 1995; 25: 2401-2407.
18. Nakane A., Minagawa T., Kayuzuki K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563-2469.
19. Havell E.A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-2899.
20. Remick D., Manohar P., Bolgos G., Rodriguez J., Moldawer L., Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality but not the lethality of cecal ligation and puncture. Shock 1995; 4: 89-95.
21. Bagby G.J., Plessala K.J., Wilson L.A., Thompson J.J., Nelson S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163: 83-88.
22. Echtenacher B., Mänel D.N., Hültner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 38:75-77.
23. Tracey K.J., Beutler B., Lowry S.F.et al.Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474.
24. van der Poll T., Büller H.R., ten Cate H.et al.Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
25. Abraham E., Wunderink R., Silverman H.et al.Efficacy and safety of monoclonal antibody to tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273: 934-941.
26. Cohen J., Carlet J. INTERSEPT: an international multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
27. Fisher Jr C.J., Agosti J.M., Opal S.M.et al.Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697-1702.
28. Bucklin S.E., Morrison D.C. Differences in efficacy among cell wall-active antibiotics in a mouse model of Gram-negative sepsis. J Infect Dis 1995; 172: 1519-1527.
29. Gonzalez J.C., Johnson D.C., Mornson D.C., Freudenberg M.A., Galanos C., Silverstein R. Endogenous and exogenous glucocorticoids have different roles in modulating endotoxin lethality in D-galactosamine-sensitized mice. Infect Immun 1993; 61: 970-974.
30. Mornson D.C., Silverstein R., Bright S.W., Chen T-Y., Flebbe L.M., Lei M-G. Monoclonal antibody to mouse lipopolysaccharide receptor protects mice against the lethal effects of endotoxin. J Infect Dis 1990; 162: 1063-1068.
31. Silverstein R., Turley B.R., Christoffersen C.A., Johnson D.C., Morrison D.C. Hydrazine sulfate protects D-galactosamine-sensitized mice against endotoxin and tumor necrosis factor/cachectin lethality: evidence of a role for the pituitary. J Exp Med 1991; 173: 357-365.
32. Silverstein R., Mornson D.C. Quantitative analysis of uridine protection in the D-galactosamine model of murine endotoxin lethal shock. J Endotoxin Res 1996; 3 (Suppl): 61.
33. Galanos C., Freudenberg M.A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979; 76: 5939-5943.
34. Galanos C., Freudenberg M.A., Katchinski T., Salomao R., Mossmann H., Kumazawa Y. Tumor necrosis factor and host response to endotoxin. In: Ryan J.L., Morrison D.C. Eds. Bacterial Endotoxic Lipopolysaccharides, Vol II, Immunopharmacology and Pathophysiology. Boca Raton: CRC Press 1992; 75-104.
35. Reed L.J., Muench H. A. A simple method of estimating fifty percent endpoints. Am J Hygiene 1938; 27: 493-497.
36. Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
37. Berry L. j., Smythe D.S. Effects of bacterial endotoxins on metabolism. VII. Enzyme induction and cortisone protection. J Exp Med 1964; 120: 721-732.
38. Galanos C., Freudenberg M.A. Tumor necrosis factor mediates endotoxin shock: the protective effects of antibodies and cortisone. In: Bonavida B., Granger G. Eds. Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy. Basel: Karger, 1990; 187-193.
39. Silverstein R. The endocrine response to endotoxin. In: Ryan J.L., Mornson D.C. Eds. Bacterial Endotoxic Lipopolysaccharides, Vol II, Immunopharmacology and Pathophysiology. Boca Raton: CRC Press, 1992; 295-309.
40. Beutler B., Krochin N., Milsark I.W., Luedke C., Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977-979.
41. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-ĸB activity through induction of IĸB synthesis. Science 1995; 270: 286-290.
42. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin Jr A.S. Role of transcriptional activation of IĸBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-286.
43. Opal S.M., Cross A., Gemski P., Lyhte L.W. Survey of purported virulence factors of Escherichia coli isolated from blood, urine and stool. Eur J Clin Microbiol Infect Dis 1988; 7: 425-427.
44. Echtenacher B., Hültner L., Männel D.N. Cellular and molecular mechanisms of TNF protection in septic peritonitis. J Inflamm 1996; 47: 85-89.
45. Opal S.M., Cross A.S., Jhung J.W.et al.Potential hazards of combination immunotherapy in the treatment of experimental shock. J Infect Dis 1996; 173: 1415-1421.